AKT inhibitor VIII

AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity with IC50s of 58 nM, 210 nM, and 2119 nM, respectively.

Product Specifications

CAS Number

[612847-09-3]

Product Name Alternative

AKTi-1/2

UNSPSC

12352005

Hazard Statement

H302, H410

Target

Akt; Apoptosis

Type

Reference compound

Related Pathways

Apoptosis; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/AKT-inhibitor-VIII.html

Purity

98.97

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

O=C1NC2=CC=CC=C2N1C3CCN(CC3)CC4=CC=C(C=C4)C5=NC6=CC7=C(C=C6N=C5C8=CC=CC=C8)N=CN7

Molecular Formula

C34H29N7O

Molecular Weight

551.64

Precautions

H302, H410

References & Citations

[1]Lindsley, et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. (2005), 15 (3), 761-764.|[2]Zhong Z, et al. Furanodiene, a Natural Product, Inhibits Breast Cancer Growth Both in vitro and in vivo. Cell Physiol Biochem. 2012;30 (3) :778-90. Epub 2012 Aug 2.|[3]Leonardo Romorini, et al. AKT/GSK3β signaling pathway is critically involved in human pluripotent stem cell survival. Sci Rep. 2016; 6: 35660